Glaucoma is a group of eye conditions that can damage the optic nerve and cause progressive vision loss. Elevated intraocular pressure (IOP) is a major risk factor. Therefore, controlling eye pressure plays an important role in managing glaucoma.
Latanoprost API in glaucoma treatment supports the development of ophthalmic medicines that lower elevated intraocular pressure. Pharmaceutical manufacturers use Latanoprost as an active ingredient in eye-drop formulations for open-angle glaucoma and ocular hypertension.
Latanoprost belongs to the prostaglandin F2α analogue class. It helps increase aqueous humour drainage and provides a sustained pressure-lowering effect.
This article explores Latanoprost’s mechanism of action, therapeutic applications, clinical properties and pharmaceutical quality considerations.
1. What Is Latanoprost API?
Latanoprost is a synthetic prostaglandin F2α analogue. Pharmaceutical manufacturers use this compound as an active pharmaceutical ingredient (API) in ophthalmic medicines.
Latanoprost acts as a prodrug. After administration, enzymes in the cornea convert it into its active acid form. The active compound then interacts with prostaglandin FP receptors and increases aqueous humour outflow.
As a result, Latanoprost-containing medicines help reduce elevated intraocular pressure.
For pharmaceutical specifications and supply enquiries, explore Latanoprost API from Chemignition Laboratory.
Chemical and Pharmaceutical Properties
| Property | Details |
|---|---|
| Product name | Latanoprost |
| CAS number | 130209-82-4 |
| Molecular formula | C₂₆H₄₀O₅ |
| Molecular weight | 432.59 g/mol |
| Chemical class | Prostaglandin F2α analogue |
| Pharmacological action | Increases aqueous humour outflow |
| Therapeutic applications | Open-angle glaucoma and ocular hypertension |
| Common finished dosage form | Ophthalmic solution |
Important: Latanoprost API is the raw pharmaceutical ingredient. Patients use finished ophthalmic medicines that contain Latanoprost, not the raw API itself.
2. Understanding Glaucoma and Intraocular Pressure
The eye continuously produces aqueous humour, a transparent fluid that supports normal eye function.
This fluid flows through the anterior part of the eye and leaves through drainage pathways.
When fluid outflow becomes insufficient, intraocular pressure may rise. Elevated pressure can increase the risk of optic nerve damage, although glaucoma can also develop at pressures within the statistically normal range.
Over time, optic nerve damage may lead to irreversible visual field loss.
Why Does Intraocular Pressure Matter?
Intraocular pressure is an important modifiable risk factor in glaucoma management.
Lowering IOP helps reduce the risk of disease progression. Consequently, ophthalmologists regularly monitor eye pressure, optic nerve health and visual fields when evaluating treatment effectiveness.
Latanoprost-containing medicines help manage elevated pressure by improving aqueous humour drainage.
3. Latanoprost Mechanism of Action in Glaucoma
The Latanoprost mechanism of action involves increasing the outflow of aqueous humour from the eye.
Unlike medicines that primarily reduce aqueous humour production, Latanoprost mainly improves fluid drainage through the uveoscleral pathway.
How Does Latanoprost Work?
- Ophthalmic administration: The patient applies the prescribed Latanoprost eye drops.
- Corneal absorption: Latanoprost passes through the cornea.
- Prodrug activation: Corneal enzymes convert Latanoprost into its active acid form.
- Receptor interaction: The active acid interacts with prostaglandin FP receptors.
- Increased fluid outflow: This activity promotes aqueous humour drainage, primarily through the uveoscleral pathway.
- Reduced eye pressure: Improved drainage helps lower intraocular pressure.
Through this mechanism, Latanoprost supports long-term IOP management in appropriate patients.
However, the medicine cannot reverse existing optic nerve damage.
4. Therapeutic Uses of Latanoprost in Ophthalmology
Healthcare professionals prescribe Latanoprost-containing ophthalmic medicines to reduce elevated intraocular pressure in suitable patients.
4.1 Open-Angle Glaucoma
Open-angle glaucoma is a common form of glaucoma. It often develops gradually and may not produce noticeable symptoms during its early stages.
Latanoprost helps lower intraocular pressure by increasing aqueous humour outflow.
Therefore, ophthalmologists commonly consider prostaglandin analogues, including Latanoprost, when selecting pressure-lowering treatment.
Treatment decisions depend on the patient’s clinical condition, treatment goals and response.
4.2 Ocular Hypertension
Ocular hypertension refers to elevated intraocular pressure without established glaucomatous optic nerve damage.
Not every patient with ocular hypertension requires medication. However, clinicians may recommend treatment when individual risk factors justify pressure reduction.
Latanoprost ophthalmic solution can help lower IOP in patients who require treatment.
4.3 Long-Term Intraocular Pressure Management
Glaucoma often requires ongoing treatment and regular monitoring.
Latanoprost provides a sustained pressure-lowering effect with its recommended once-daily administration schedule.
Nevertheless, treatment response varies. Patients should follow their ophthalmologist’s instructions and attend regular examinations.
5. Latanoprost Ophthalmic Formulation and Dosage
Pharmaceutical manufacturers commonly formulate Latanoprost as a 0.005% ophthalmic solution, equivalent to 50 micrograms per millilitre.
The prescribing information for conventional Latanoprost ophthalmic solutions recommends one drop in the affected eye or eyes once daily in the evening.
More frequent administration may reduce the pressure-lowering effect. Therefore, patients should follow the prescribed dosing schedule.
API Concentration vs Finished Product Concentration
Pharmaceutical manufacturers must distinguish the raw API from the finished medicine.
The 0.005% concentration describes the strength of a conventional finished ophthalmic formulation.
It does not represent the purity, assay or specification of bulk Latanoprost API.
Finished formulations also require appropriate excipients, packaging, sterility controls and product-specific stability evaluation.
6. How Quickly Does Latanoprost Reduce Eye Pressure?
Latanoprost-containing ophthalmic medicines generally begin lowering intraocular pressure within approximately three to four hours after administration.
The maximum pressure-lowering effect usually occurs after eight to twelve hours.
Furthermore, the effect can continue for at least 24 hours.
These characteristics support the recommended once-daily dosing schedule.
However, patients may respond differently. Ophthalmologists assess treatment effectiveness through clinical monitoring rather than relying only on expected response times.
7. Pharmacological Properties of Latanoprost
Understanding Latanoprost pharmacology helps explain its therapeutic activity.
Absorption and Activation
Following topical administration, Latanoprost passes through the cornea.
Corneal esterases convert the prodrug into Latanoprost acid, its pharmacologically active form.
The active acid then reaches ocular tissues and produces its pressure-lowering effect.
Distribution
Latanoprost acid reaches the aqueous humour, and laboratory tests can also detect it briefly in systemic circulation.
However, topical ophthalmic administration generally results in limited systemic exposure.
Metabolism
The liver primarily metabolises Latanoprost acid that reaches systemic circulation through fatty acid beta-oxidation pathways.
Elimination
The kidneys eliminate most of its metabolites.
The active acid has a short plasma half-life of approximately 17 minutes.
Importantly, this short plasma half-life does not represent the duration of the medicine’s effect on intraocular pressure.
8. Safety and Precautions of Latanoprost Ophthalmic Medicines
Latanoprost-containing medicines have an established role in glaucoma treatment. However, patients may experience adverse effects.
Common Side Effects
Some patients may experience:
- Eye redness
- Mild irritation or discomfort
- Itching or a foreign-body sensation
- Blurred vision
- Changes in eyelash appearance
The type and severity of adverse effects vary between patients.
Iris Pigmentation
Latanoprost may gradually increase brown pigmentation in the iris.
In some patients, this change becomes permanent. Therefore, healthcare professionals should explain this possibility before treatment.
Eyelash Changes
Latanoprost may increase eyelash length, thickness, pigmentation or number.
These effects relate to the finished medicine’s pharmacological activity.
Additional Precautions
Healthcare professionals should consider relevant precautions in patients with ocular inflammation, certain risk factors for macular oedema or a history of herpetic keratitis.
Patients should also follow the approved prescribing information regarding hypersensitivity, pregnancy and other clinical considerations.
Note: This safety discussion applies to Latanoprost-containing ophthalmic medicines. Raw Latanoprost API requires separate occupational handling controls.
9. Importance of Latanoprost API Quality in Pharmaceutical Manufacturing
Pharmaceutical manufacturers must evaluate the quality of Latanoprost API before using it in ophthalmic formulations.
Appropriate specifications and analytical testing help support consistent manufacturing and product development.
9.1 Identity Testing
Identity testing confirms the chemical identity of Latanoprost.
Manufacturers use suitable analytical procedures according to the applicable specifications and validated methods.
9.2 Assay Determination
Assay testing determines the amount of Latanoprost present in the API sample.
Manufacturers compare the result with the applicable acceptance criteria.
9.3 Related Substances and Impurities
Impurity testing helps manufacturers evaluate related substances and degradation products.
These controls are particularly important when developing products that require consistent pharmaceutical quality.
9.4 Stability and Storage
Manufacturers should establish appropriate API storage conditions using relevant stability data.
Temperature, light exposure, packaging and other environmental factors may influence product stability.
However, storage instructions for finished Latanoprost eye drops should not automatically determine raw API storage requirements.
9.5 Quality Documentation
Pharmaceutical buyers commonly review available quality documents before sourcing an API.
These may include:
- Certificate of Analysis (COA)
- Product specifications
- Available stability information
- Relevant analytical documentation
- Applicable regulatory support documents
Documentation availability and requirements depend on the product, supplier and intended market.
For product-specific information, visit the Chemignition Laboratory Latanoprost API product page.
10. Latanoprost API in Ophthalmic Pharmaceutical Development
Latanoprost API supports the development and manufacture of ophthalmic medicines for reducing elevated intraocular pressure.
However, pharmaceutical manufacturers must consider more than API identity and assay.
Key Formulation Considerations
API compatibility: Manufacturers evaluate interactions between Latanoprost and formulation excipients.
Chemical stability: Development teams investigate degradation pathways and establish suitable formulation conditions.
Container-closure compatibility: Manufacturers assess packaging materials and their suitability for the finished ophthalmic product.
Sterility assurance: Ophthalmic solutions require appropriate manufacturing controls and microbiological quality.
Regulatory requirements: Manufacturers must meet the applicable requirements for their intended markets.
These activities help establish an appropriate finished-product quality profile.
Importantly, API quality testing alone does not demonstrate the safety, efficacy or regulatory acceptability of a finished ophthalmic medicine.
11. Latanoprost API Supplier — Chemignition Laboratory
Chemignition Laboratory provides product information and commercial enquiry support for pharmaceutical businesses sourcing Latanoprost API.
When evaluating an API supplier, pharmaceutical manufacturers should consider product specifications, quality documentation, packaging, storage requirements and supply arrangements.
These factors help procurement and quality teams assess material suitability for their intended applications.
Explore Latanoprost API — Chemignition Laboratory for product details and enquiries.
Conclusion
Latanoprost API in glaucoma treatment plays an important role in the development of ophthalmic medicines that reduce elevated intraocular pressure.
Its mechanism of action increases aqueous humour outflow, while its sustained pressure-lowering effect supports once-daily administration in conventional finished formulations.
For pharmaceutical manufacturers, API identity, assay, impurity control, stability and documentation remain important quality considerations.
Learn more about Latanoprost API from Chemignition Laboratory and contact the team for product information and commercial enquiries.
Medical information notice: This article provides general scientific and pharmaceutical information. It does not replace professional medical advice, individual treatment decisions or approved prescribing information.
FAQs
What is Latanoprost API used for?
Pharmaceutical manufacturers use Latanoprost API to develop ophthalmic medicines that lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
How does Latanoprost work in glaucoma?
Latanoprost increases aqueous humour outflow, primarily through the uveoscleral pathway. This action helps reduce intraocular pressure.
Is Latanoprost a prostaglandin analogue?
Yes. Latanoprost is a synthetic prostaglandin F2α analogue.
What is the usual concentration of Latanoprost eye drops?
Conventional Latanoprost ophthalmic solutions commonly contain 0.005% Latanoprost, equivalent to 50 micrograms per millilitre.
Can Latanoprost cure glaucoma?
No. Latanoprost helps lower intraocular pressure, but it cannot reverse existing optic nerve damage or restore vision lost through glaucoma.
How long does Latanoprost take to work?
The pressure-lowering effect generally begins within three to four hours and reaches its maximum after approximately eight to twelve hours.
Why is Latanoprost API quality important?
API quality testing helps pharmaceutical manufacturers assess identity, assay, impurities and other relevant material attributes before formulation.
Is Latanoprost API the same as Latanoprost eye drops?
No. Latanoprost API is the raw active pharmaceutical ingredient. Latanoprost eye drops are finished medicines containing the API and other formulation components.
What is the CAS number of Latanoprost?
The CAS Registry Number of Latanoprost is 130209-82-4.
